Marseille-Kliniken AG

EANS-Adhoc: - Marseille-Kliniken Group disposing of its rehabilitation division - The transaction includes all rehabilitation clinics with a total of 1,269 beds - Sale generates a book gain in a lower double-digit EUR million range

--------------------------------------------------------------------------------
  ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
  adhoc with the aim of a Europe-wide distribution. The issuer is solely
  responsible for the content of this announcement.
-------------------------------------------------------------------------------- 

Disposing of business division

21.04.2010

Berlin, 21 April 2010. Marseille-Kliniken Group (Prime Standard, ISIN DE 0007783003, MKA) has, as already announced some time ago, disposed of all rehabilitation clinic operations, thereby discontinuing the Group´s rehabilitation business. The closing of the sale depends on the approval of the annual general meeting of Karlsruhe Sanatorium AG as well as the lessor´s consent. This is to be completed by the beginning of May 2010. Capacities of 1,269 beds at seven locations in Germany are being sold.

The transaction is impacting the investments in the rehabilitation clinics operated by Karlsruhe Sanatorium AG, a subsidiary of Marseille-Kliniken AG. It includes the Gotthard-Schettler-Klinik and REHA-Klinik Sigmund Weil, both located in Bad Schönborn, the specialist clinic for mental conditions Ortenau in Zell am Harmersbach, the clinic in Bad Herrenalb, the specialist clinic for psychosomatic conditions Schömberg as well as the psychosomatic clinic Kinzigtal in Gengenbach. Marseille-Kliniken AG also disposed of its investments in the rehabilitation companies Algos Fachklinik in Bad Klosterlausnitz, the sports and rehabilitation center Harz and Teufelsbad specialist clinic Blankenburg, both in Blankenburg/Harz. The clinic locations are each operated as limited companies (GmbH) and their shares were sold as part of this transaction.

In return, Marseille-Kliniken Group will be recording a significant book gain amounting to a lower double-digit EUR million scope. Both parties agreed not to disclose the exact purchase amount involved.

Marseille-Kliniken Group is making the sale to a joint venture held by funds which financial investor AUCTUS Capital Partners AG consults, and the existing management team around CEO Berthold Müller and Medical Director Professor Dr. Ulrich T. Egle and Professor Dr. Bernd E. Fromm. AUCTUS is Germany´s leading SME investment company and commands considerable expertise in the field of healthcare.

The Rehabilitation division is profitable, it has not been part of the core business of Marseille-Kliniken Group in the recent past. The company has been reviewing a sale of the division for some time as a result. Generated inflows are to be invested in further developing the Care core business.

End of ad hoc release

end of announcement                               euro adhoc
-------------------------------------------------------------------------------- 

Further inquiry note:

Hillermann Consulting
Christian Hillermann
Investor Relations for Marseille-Kliniken AG
Poststraße 14/16
20354 Hamburg
Germany
Tel.: +49-(0)40 / 320 279-10
Fax: +49-(0)40 / 320 279-114
www.hillermann-consulting.de

Marseille-Kliniken AG
Dr. Ute Buchheim
Friedrich-Ebert-Str. 65
33330 Gütersloh
Germany
Tel.: +49-(0)5241 / 90 39-35
Fax: +49-(0)5241 / 90 39-39
www.marseille-kliniken.com

Branche: Pharmaceuticals
ISIN: DE0007783003
WKN: 778300
Index: CDAX, Classic All Share, Prime All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Stuttgart / free trade
Düsseldorf / free trade
Hamburg / regulated dealing

Original-Content von: Marseille-Kliniken AG, übermittelt durch news aktuell

Weitere Meldungen: Marseille-Kliniken AG

Das könnte Sie auch interessieren: